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Abstract 
Background: Observational studies have suggested an association between circulating vitamin 
D concentrations [25(OH)D] and risk of breast and prostate cancer, which was not supported by 
a recent Mendelian randomization analysis comprising 15,748 breast and 22,898 prostate cancer 
cases. Demonstrating causality has proven challenging, and one common limitation of MR 
studies is insufficient power.  
Methods: We aim to determine if circulating concentrations of vitamin D are causally associated 
with the risk of breast and prostate cancer, by using summary level data from the largest-ever 
genome-wide association studies conducted on vitamin D (N=73,699), breast cancer 
(Ncase=122,977) and prostate cancer (Ncase=79,148). We constructed a stronger instrument using 
six common genetic variants (as compared with the previous four variants), and applied several 
two-sample MR methods. 
Results: We found no evidence to support a causal association between 25(OH)D and risk of 
breast cancer [OR per 25nmol/L increase, 1.02 (95%CI: 0.97-1.08), P=0.47], estrogen receptor 
(ER)+ [1.00 (0.94-1.07), P=0.99] or ER [1.02 (0.90-1.16), P=0.75] subsets; prostate cancer 
[1.00 (0.93-1.07), P=0.99] or the advanced subtype [1.02 (0.90-1.16), P=0.72] using the inverse 
variance weighted method. Sensitivity analyses did not reveal any sign of directional pleiotropy. 
Conclusion: Despite its almost five-fold augmented sample size and substantially improved 
statistical power, our MR does not convincingly support a causal effect of circulating 25(OH)D 
concentrations on breast or prostate cancer risk. However, we can still not exclude a modest or 
non-linear effect of vitamin D. Future studies may be designed to understand the effect of 
vitamin D in subpopulations with a profound deficiency. 
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Key message 
We did not find a putative causal role of circulating vitamin D concentrations in the risk of breast 
or prostate cancer. 
We still cannot exclude a modest or non-linear effect of vitamin D on malignant disease. 
Future work on vitamin D may be focused on cancer mortality or on subpopulations with a 
profound deficiency. 
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Introduction 
Vitamin D is a fat-soluble vitamin and steroid pro-hormone that plays an essential role in bone 
health.
1
 Its biologically active form 1,25-hydroxyvitamin D regulates multiple signaling 
pathways involved in cell proliferation, apoptosis, differentiation and inflammation, and is 
therefore believed to have an anti-carcinogenic property.
2
 
Epidemiologic evidence on the association of circulating vitamin D and risk of breast and 
prostate cancer, the two most common malignancies in women and men, remains inconclusive. 
A meta-analysis aggregating data from 24 prospective studies (Ncase=31,867) identified a pooled 
relative risk of breast cancer for the highest (>31ng/ml) vs. lowest (<18ng/ml) blood 25-
hydroxyvitamin D [25(OH)D] of 0.92 (95%CI: 0.83-1.02).
3
 Another meta-analysis combining 
data from 19 prospective studies (Ncase=12,824) found a summary relative risk of 1.04 (95% CI: 
1.02-1.06) per 10 ng/ml increment in circulating 25(OH)D concentration.
4
 Inferring causality 
from such studies is challenging because it is difficult to exclude reverse causality, confounding 
or measurement error. 
Although the effect of circulating 25(OH)D on cancer risk can be demonstrated by traditional 
randomized controlled trials (RCT), large-scale RCTs are not currently widely available due to 
high cost and long duration. In the Women’s Health Initiative trial, 36,282 postmenopausal 
women were randomized to 400 IU vitamin D or placebo, and a hazard ratio of 0.96 (95%CI: 
0.85-1.09, P=0.55) for breast cancer was observed after 7 years’ follow up.5 For prostate cancer, 
only two comprehensive ongoing trials involving both men and women, the “VITAL” launched 
in 2010 (N=25,871)
6
 and the “D-Health” launched in 2014 (N=21,315),7 will provide an 
opportunity to clarify the role of vitamin D on male health outcomes upon completion. Yet, both 
RCTs are likely to be underpowered given the relatively low prostate cancer incidence. 
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Mendelian randomization (MR) analysis overcomes the limitations of conventional approaches 
by using genetic variants (single nucleotide polymorphisms, SNPs) as instrumental variables 
(IVs) for assessing the causal effect of a risk factor (exposure) on an outcome from observational 
data.
8
 A two-sample MR obtain IV-exposure and IV-outcome associations from two different 
sets of participants. A recent two-sample MR conducted by Dimitrakopoulou et al. included 
summary results from large collaborative networks (Ncase=70,563) to examine the causal role of 
vitamin D on seven cancers (breast [Ncase=15,748], prostate [Ncase=22,898], lung [Ncase=12,537], 
colorectal [Ncase=11,488], ovarian [Ncase=4,369], pancreatic [Ncase=1,896] and neuroblastoma 
[Ncase=1,627]). This study observed little evidence that genetically predicted 25(OH)D was 
associated with the risk of any cancer [OR per 25nmol/L increase for breast: 1.05 (95%CI: 0.89-
1.24); prostate: 0.89 (95%CI: 0.77-1.02)].
9
 However, the Dimitrakopoulou et al. study used four 
genetic variants identified from an earlier SUNLIGHT consortium genome-wide association 
study (GWAS).
10
 With the rapid expansion in sample sizes of GWAS, two additional vitamin D 
associated loci have been recently identified.
11
 Incorporating these loci could improve the 
strength of genetic instrument and both the accuracy and precision of MR estimates. The 
statistical power can be further improved by using summary genetic data for breast and prostate 
cancer from recent larger GWASs.
12–14
 
Therefore, we conducted an updated two-sample MR analysis to examine the effect of 25(OH)D 
on breast and prostate cancer. Six genetic variants associated with plasma 25(OH)D 
concentration were used as IVs. Summary statistics for the IV-exposure were extracted from the 
largest vitamin D GWAS involving 73,699 individuals.
11
 Summary statistics for the IV-outcome 
were extracted from the largest GWASs for breast (122,977 cases and 105,974 controls) and 
prostate cancer (79,148 cases and 61,106 controls) conducted by the OncoArray network.
15
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Methods 
Data for IV-exposure 
We retrieved summary data for the association between six SNPs and circulating 25(OH)D 
concentration from the SUNLIGHT meta-GWAS involving 79,366 discovery samples and 
42,757 replication samples of European ancestry. Genome-wide analyses were performed within 
each cohort according to a uniform analysis plan. Specifically, additive genetic models using 
linear regression on natural-log transformed 25(OH)D were fitted, and a fixed-effects inverse 
variance weighted meta-analysis across the contributing cohorts was performed, with control for 
population structure within each cohort and quality control thresholds of minor allele frequency 
(MAF)>0.05, imputation info score>0.8, Hardy-Weinberg equilibrium (HWE)>110-6, and a 
minimum of 10,000 individuals contributing to each reported SNP-phenotype association. 
Information regarding the quality control and statistical analyses has been reported previously.
11
 
Among the six SNPs, four were previously identified as being robustly associated with vitamin 
D (rs3755967 at GC, rs12785878 at NADSYN1/DHCR7, rs10741657 at CYP2R1, rs17216707 at 
CYP24A1). The other two were newly identified by the discovery sample (rs10745742 at 
AMDHD1, rs8018720 at SEC23A) and validated in the replication sample. 
Data for IV-outcome 
We retrieved summary data for associations of the six vitamin D proxy SNPs with breast and 
prostate cancer from the currently largest meta-GWAS of these outcomes conducted by the 
OncoArray network,
15
 a large-scale collaboration that was established to understand the genetic 
architecture and biological mechanisms underlying five common cancers (breast, prostate, 
ovarian, colorectal and lung cancer). A total of 447,705 individuals of European ancestry were 
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genotyped on a custom Illumina array, and imputed to the 1000 Genomes Project reference panel. 
For each cancer type, results from individual GWAS were combined by fixed-effects inverse 
variance weighted meta-analysis, with control for population stratification within each cohort 
and quality control thresholds of MAF>0.01, imputation info score>0.3 and HWE>110-12. 
Information regarding the quality control and statistical analyses has been reported previously.
12–
14
 
For breast cancer, 122,977 cases (105,974 controls) were involved, of which, 69,501 were 
estrogen receptor (ER)+ cases and 21,468 were ER cases; for prostate cancer, 79,148 cases 
(61,106 controls) were involved, of which 15,167 were diagnosed with advanced prostate cancer 
(defined as Gleason Score 8+ or death from the disease or metastatic disease (i.e. M1) or prostate 
specific antigen values > 100 ng/ml). Our current sample size was 4.6-fold higher than that in 
Dimitrakopoulou et al.
9
. 
Statistical analysis 
MR uses SNPs as proxies for risk factors, assuming that SNPs are randomly allocated at 
conception, mirroring a randomization process; and that SNPs always precede disease onset thus 
eliminating reverse causality. Three important assumptions need to be met to ensure a valid IV.
16
 
The first is the relevance assumption, that the IVs should be strongly associated with the 
exposure; the second assumption requires no association between IVs and confounders of the 
exposure-outcome relationship; and the third is the exclusion restriction assumption, indicating 
that genetic variants should affect the outcome only through the exposure. If all MR assumptions 
are satisfied then a causal estimation can be made based on the observed IV-exposure and IV-
outcome association. 
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We conducted a two-sample MR to test for a potential causal relationship between circulating 
25(OH)D and risk of breast and prostate cancer. We also investigated cancer subtypes including 
ER+ and ER breast cancer and advanced prostate cancer. We applied a number of MR methods 
including an inverse variance weighted average approach (IVW),
17
 a maximum likelihood 
method,
18
 MR-Egger regression,
19
 and a weighted median approach.
20
 
For each of the k genetic variants (IVs), the estimate of genetic association with the exposure is 
represented as ˆXk with standard error Xk , and the estimate of genetic association with the 
outcome is represented as ˆYk with standard error Yk . The IVW estimator can be motivated as a 
weighted average of the ratio estimates 
ˆ
ˆ
Yk
Xk


for each variant, weighted using the reciprocal of an 
approximate expression for their asymptotic variance
2
2ˆ
Yk
Xk


, as shown by the formula below. To 
evaluate potential heterogeneity among causal effects of different variants, we employed the Q 
test, P-value < 0.05 was considered as the existence of heterogeneity. 
The causal estimate 
2
2 2
ˆ ˆ
ˆ
ˆ
Xk Yk Ykk
IVW
Xk Ykk
  

 





 
The approximate standard error of the estimate   2 2
1ˆse
ˆIVW
Xk Ykk

  


 
Complementary to IVW, we also adopted the maximum likelihood method. When the genetic 
associations with the exposure are precisely estimated, both approaches give identical results. 
When there is considerable imprecision in the estimates, causal effect estimates from the IVW 
are over-precise, whereas the likelihood method gives appropriately-sized confidence intervals. 
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In addition, we performed MR-Egger regression to test for bias due to directional pleiotropy, 
where the average of the direct effects of the tested genetic variants on outcome is non-zero (i.e. 
a violation of exclusion restriction assumption). Under the INstrument Strength Independent of 
Direct Effect (InSIDE) assumption, the intercept of a weighted regression of ?̂?𝑦𝑘 on ?̂?𝑥𝑘 will be 
different than zero in the presence of directional pleiotropy, and the slope of that regression will 
be a consistent estimate of the causal effect of X on Y.
21
 Complementary to MR-Egger, we also 
employed a weighted median method to derive causal effect estimates. This method provides 
consistent estimates even when up to 50% of the analyzed genetic variants are invalid IVs. We 
also employed a multivariable MR approach
22
 to adjust for potential horizontal pleiotropy acting 
in particular through BMI, because rs10741657 has been associated with BMI (P=0.01), and 
BMI has been associated with 25(OH)D concentrations
23
 and breast cancer risk
24
. Publicly 
available genetic data for BMI were retrieved from the GIANT consortium for 339,000 
individuals (95% were of European descent).
25
 
Further, we performed a sensitivity analysis where we excluded one SNP at-a-time, and 
performed IVW on the rest five SNPs to identify the potential influence of outlying variants on 
the estimates. Finally, we estimated the power of our study according to a method suggested by 
Brion et al.
26
. The six 25(OH)D associated SNPs collectively explained 2.84% of the variance of 
circulating vitamin D concentration. We fixed the type-I error rate at 0.05. 
Results 
Table 1 shows the sample size in the current analysis for each cancer and subtype. The number 
of overall breast cancer cases was 122,977, of which 69,501 were ER+ cases and 21,468 were 
ER cases. The number of overall prostate cancer cases was 79,148, of which 15,167 had 
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advanced disease. Under the current sample size, our study had 80% power to detect a causal 
effect of a relative 7% (i.e. ORs of 0.93 or less) decrease in breast cancer risk per 25nmol/L 
increase of 25(OH)D and 8% for prostate cancer (i.e. ORs of 0.92); corresponding estimates for 
ER+ breast cancer, ER breast cancer and advanced prostate cancer were 8%, 12% and 13% 
relative reductions (i.e. ORs of 0.92, 0.88 and 0.87). We also presented power estimations for a 
range of proportions of 25(OH)D variation explained by the six genetic variants.  
Table 2 presents the information on the association of six SNPs (rs3755967, rs12785878, 
rs10741657, rs17216707, rs10745742 and rs8018720) with 25(OH) D concentration and cancers. 
There was no evidence that any of the individual vitamin D associated SNPs were also 
associated with breast or prostate cancer. We did not find that the genetic instrument for 
circulating 25(OH)D concentration was associated with the risk of breast [IVW per 25nmol/L 
increase: 1.02 (95%CI: 0.97-1.08)] or prostate cancer [IVW: 1.00 (95%CI: 0.93-1.07)], breast 
cancer subtypes [ER+: 1.00 (95%CI: 0.94-1.07); ER: 1.02 (95%CI: 0.90-1.16)] or advanced 
prostate cancer [IVW: 1.02 (95%CI: 0.90-1.16)]. The maximum likelihood method generated 
very similar results. We did not detect heterogeneity among the causal estimates of the six 
variants (Phet=0.45 and 0.80 for overall breast and prostate cancer; 0.61 and 0.14 for ER+ and 
ER subset; 0.58 for advanced prostate cancer), indicating little evidence for the existence of 
SNP-specific horizontal pleiotropy. Further, we did not identify aggregated directional pleiotropy 
using MR-Egger (Pintercept= 0.92 and 0.88 for overall breast and prostate cancer; 0.82 and 0.70 for 
ER+ and ER subset; 0.72 for advanced prostate cancer; the intercepts with 95%CIs are shown 
in Table 3), although this method has low statistical power when few genetic instruments are 
used. Consistent with IVW, estimates from MR-Egger and weighed median approach did not 
provide any evidence of a causal effect of circulating vitamin D on prostate or breast cancer 
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(Table 3). Multivariable IVW estimates controlling for BMI were almost identical with the 
classical IVW approach (results not shown). 
Similar results were observed in the leave-one-out analysis where we iteratively removed one 
SNP each time and performed IVW using the remaining five SNPs (Table 4). 
Discussion 
In this study, we used an updated and stronger instrumental variable constructed from six SNPs 
and capitalized on the summary statistics of the largest meta-GWAS conducted for breast and 
prostate cancers in European populations. We aimed to determine whether the relationship 
between 25(OH)D and risk of two cancers was causal employing a range of two-sample MR 
methods. However, none of these analyses suggested a causal relationship between circulating 
25(OH)D concentration and breast or prostate cancer risk. 
Despite previous retrospective observational studies suggesting an inverse association between 
higher circulating 25(OH)D concentrations and breast cancer risk, such a relationship has not 
been firmly supported by evidence from prospective epidemiological studies. Bauer et al. meta-
analyzed 9 prospective studies (Ncase=5,206) and identified weak evidence of an association 
between circulating 25(OH)D and risk of postmenopausal [RR per 5ng/mL (approximately 
12.5nmol/L) 0.97 (95%CI: 0.93-1.00)], but not premenopausal [0.99 (95%CI: 0.97-1.04)] breast 
cancer.
27
 Similar results were observed in a meta-analysis conducted by Wang et al. that 
aggregated data over 13 prospective studies (Ncase=9,110), where circulating 25(OH)D was 
inversely associated with postmenopausal breast cancer [RRhighest vs. lowest quantile 0.85 (95%CI: 
0.75-0.96)], and with similar but imprecise estimates for premenopausal breast cancer [0.84 
(95%CI: 0.52-1.35)].
28
 When the sample size was further increased to 31,867 individuals and 
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with a careful inclusion criteria as in the meta-analysis conducted by Kim et al., little evidence of 
a significant association was reported for either postmenopausal [RRhighest vs. lowest category 0.96 
(95%CI: 0.85-1.02)] or premenopausal [0.82 (95%CI: 0.48-1.41)] breast cancer.
3
 In agreement 
with these findings, the Women’s Health Initiative (WHI) trial of vitamin D in postmenopausal 
women did not support a role in breast cancer [HRtaker vs. non-taker 0.96 (95%CI: 0.85-1.09)].
5
 
However, it has been argued that personal use of vitamin D supplements (outside of the trial) 
may have obscured the effect. Among the 43% of WHI women who were not taking personal 
vitamin D at randomization, a reduced risk of breast cancer was observed comparing calcium 
and vitamin D supplementation to placebo [HR 0.82 (95%CI: 0.70-0.97)].
29
 Although our study 
had 80% power to detect even smaller effect sizes, ranging from 0.89 to 0.95 per 25nmol/L 
change, we did not find evidence of an association between genetically determined 25(OH)D 
concentration and risk of breast cancer. 
Results of observational studies investigating 25(OH)D with prostate cancer risk are relatively 
consistent. Xu et al. performed a meta-analysis of 17 nested case-control studies (Ncase=11,380) 
and observed an increased risk of prostate cancer [RRhighest vs. lowest category 1.18 (95%CI: 1.07-1.30), 
I-square=20.8%].
30
 A similar effect-estimate was reported by Gao et al. with improved precision 
in a meta-analysis comprising 19 prospective studies (Ncase=12,824) [RRhighest vs. lowest category 1.15 
(95%CI: 1.06-1.24), I-square=0%].
4
 In line with those findings, a large cohort consortium of 
10,018 cases and 11,052 controls examined an unweighted polygenic risk score based on four 
25(OH)D associated SNPs (rs2282679 at GC, rs6013897 at CYP24A1, rs10741657 at CYP2R1, 
rs12785878 at DHCR7). This analysis found that a greater number of high vitamin D increasing 
alleles was associated with an increased risk of aggressive prostate cancer,
31
 which might merely 
reflect metabolic events, molecular or immunological alterations relevant to prostate cancer risk. 
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Our MR found no evidence of an association between genetically predicated 25(OH)D 
concentration and risk of overall or advanced prostate cancer. 
Our previous MR study did not provide strong evidence of a causal link between 25(OH)D and 
seven cancers. That study might have been underpowered to identify small effects for some 
cancers or subgroups,
32
 as a positive association for ovarian cancer was shown in an independent 
MR with larger sample size.
33
 Insufficient power is a common limitation of MR studies, because 
the genetic variants usually explain a modest proportion of phenotypic variance. The four 
previously reported vitamin D associated SNPs could only explain 3.6%-5.2% of the variance of 
25(OH)D;
10,34
 and the six vitamin D associated SNPs identified by us, could only explain 2.84% 
out of the 7.5% overall SNP-heritability calculated using the linkage disequilibrium score 
regression analysis.
11
 Although improvement in the proportion of variability explained by IVs 
was minimal, our overall statistical power was considerably raised, using data from substantially 
augmented GWASs of breast and prostate cancer. We had 80% power at an alpha level of 0.05 to 
identify a 7% relative decreased breast cancer risk (i.e. an OR of 0.93) and an 8% relative 
decreased prostate cancer risk (i.e. an OR of 0.92) per 25nmol/L increase in circulating 25(OH)D. 
These effect sizes are comparable to the effects observed in meta-analyses of prospective studies 
for both cancers. However, it is likely that the true causal effect of 25(OH)D is even weaker – if 
the true causal effect was less than 3%, a magnitude that is probably of limited clinical relevance 
– we only had a power of 23% for breast cancer, and 15% for prostate cancer, with our current 
sample size. 
MR provides the opportunity to make causal inference between an exposure and an outcome 
using observational data. The validity of causal estimates requires several assumptions to be 
satisfied. We selected the most significant independent SNPs identified by the largest 25(OH)D 
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GWAS, so all were robustly associated with the exposure of interest. The six variants combined 
constitute a strong instrument, with an F statistic of 387. This would minimize any bias due to 
using a weak instrument in the analysis. Secondly, none of the six instrumental variables (or the 
proxy SNPs in high linkage disequilibrium with the six IVs at r
20.8) used in our analysis were 
cited by the NHGRI-EBI Catalog of published GWAS as associated with known confounders of 
cancer risk, such as BMI, smoking, alcohol consumption, mammographic density or 
inflammation at =10-5 level. However, due to the lack of individual data, we were not able to 
test the association of genetic instruments with other confounders such as physical activity, 
hormonal and lifestyle related factors, which are usually captured by questionnaires. Finally, the 
major assumption is the exclusion restriction that the genetic determinants affect cancer only 
through vitamin D concentrations. Violation of this assumption is unlikely as we employed a 
range of methods known to control for pleiotropy, and obtained highly consistent results. 
However, we are also aware that MR-Egger regression with only six SNPs could be 
underpowered to identify pleiotropy. All MR studies so far have only tested the linear effect of 
circulating vitamin D concentations in the general population. Future studies may be designed to 
understand the effect of vitamin D in subpopulations with a profound deficiency (non-linear 
effects), as well as to investigate the causal role of vitamin D in cancer progression or death. 
In conclusion, although a very small causal effect of circulating 25(OH)D concentration on 
breast and prostate cancers cannot be ruled out, our updated analysis, despite its almost five-fold 
augmented sample size and substantially improved overall statistical power, provides no 
evidence in support of a causal relationship between circulating concentrations of 25(OH)D and 
the risk of breast or prostate cancer. 
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Table1. Number of cancer cases and controls and statistical power in Mendelian randomization study of 
circulating vitamin D concentration and risk of breast and prostate cancer. 
Cancer type Cases Controls Total 
Proportion 
of cases 
Minimum detectable odds ratio 
R2=0.01 R2=0.02 R2=0.03 R2=0.04 R2=0.05 
Breast cancer 
Overall 122977 105974 228951 0.54 0.89/1.12 0.92/1.09 0.935/1.069 0.943/1.06 0.948/1.05 
ER-positive 69501 95042 164543 0.42 0.87/1.15 0.905/1.104 0.922/1.085 0.932/1.073 0.939/1.065 
ER-negative 21468 100594 122062 0.18 0.80/1.25 0.855/1.169 0.882/1.134 0.897/1.11 0.908/1.10 
Prostate cancer 
Overall 79148 61106 140254 0.56 0.86/1.16 0.90/1.11 0.92/1.09 0.93/1.08 0.94/1.07 
Advanced 15167 58308 73475 0.21 0.79/1.26 0.85/1.18 0.87/1.15 0.88/1.13 0.90/1.11 
ER: estrogen receptor. Minimum detectable odds ratio per 25nmol/L increase/decrease in 25(OH)D 
concentration: assume 80% power, 5% alpha level, and that 1% to 5% of 25(OH)D variance is explained by 
the six SNPs used in the current paper. 
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Table2. Characteristics of GWAS-identified genetic variants associated with circulating 25(OH)D concentrations and their effects in the breast and prostate cancer. 
SNPs 
Chr: pos 
(hg19) 
Locus 
Effect
/ 
Other 
allele 
Circulating Vitamin D 
Levels 
Overall Breast 
Cancer 
ER-positive Breast 
Cancer 
ER-negative Breast 
Cancer 
Prostate Cancer 
Advanced Prostate 
Cancer 
Beta 
(SE) 
P-value 
Beta 
(SE) 
P-value 
Beta 
(SE) 
P-value 
Beta 
(SE) 
P-value 
Beta 
(SE) 
P-value Beta (SE) P-value 
rs3755967 4:72609398 GC T/C 
 -0.089 
(0.0023) 
4.74E-343 
 -0.0031 
(0.0069) 
0.65 
0.0012 
(0.0082) 
0.89 
 -0.0103 
(0.0125) 
0.41 
 -0.0029 
(0.0091) 
0.75 
 -0.0114 
(0.0158) 
0.47 
rs10741657 11:14914878 CYP2R1 A/G 
0.031 
(0.0022) 
2.05E-46 
0.0075 
(0.0063) 
0.23 
0.0015 
(0.0075) 
0.84 
0.012 
(0.0115) 
0.30 
0.0031 
(0.0082) 
0.71 
0.0122 
(0.0142) 
0.39 
rs12785878 11:71167449 
NADSYN1
/ DHCR7 
T/G 
0.036 
(0.0022) 
3.80E-62 
 -0.0016 
(0.0070) 
0.82 
0.0054 
(0.0083) 
0.52 
 -0.0245 
(0.0127) 
0.054 
 -0.0111 
(0.0090) 
0.22 
 -0.0243 
(0.0154) 
0.12 
rs10745742* 12:96358529 AMDHD1 T/C 
0.0190 
(0.0020) 
2.10E-20 
0.0044 
(0.0063) 
0.49 
 -0.0011 
(0.0075) 
0.88 
0.0097 
(0.0115) 
0.40 
0.0006 
(0.0082) 
0.94 
 0.0000 
(0.0142) 
0.99 
rs8018720* 14:39556185 SEC23A C/G 
 -0.019 
(0.0027) 
1.11E-11 
0.0132 
(0.0083) 
0.11 
0.0162 
(0.0099) 
0.10 
0.0222 
(0.0152) 
0.14 
 -0.0071 
(0.0108) 
0.51 
 -0.0065 
(0.0186) 
0.73 
rs17216707 20:52732362 CYP24A1 T/C 
0.026 
(0.0027) 
8.14E-23 
0.0062 
(0.0082) 
0.45 
0.0063 
(0.0098) 
0.53 
0.0055 
(0.0150) 
0.71 
 -0.0040 
(0.0106) 
0.70 
 -0.0026 
(0.0182) 
0.88 
Reference Jiang, et al. 2018 
Michailidou, et al. 
2017 
Michailidou, et al. 
2017 
Milne, et al. 2017 
Schumacher, et al. 
2018 
Schumacher, et al. 
2018 
*Novel vitamin D GWAS-identified SNPs, beta-coefficients were extracted from the pooled analysis (discovery dataset + replication dataset). ER: estrogen receptor. 
The beta coefficients for the association between SNPs and circulating vitamin D are based on per effect allele per unit change in log 25(OH)D. To enable better comparison with results from 
observational studies, we run MR analyses after transforming these beta coefficients into the natural scale (nmol/L) using a formula suggested by Rodriguez-Barranco et al. BMC Med Res 
Methodol 2017 Mar 17;17(1):44. 
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Table 3. Mendelian Randomization estimates between genetically predicted 25(OH)D concentrations 
and cancer risk using multiple 25(OH)D GWAS-identified variants. 
Cancer type Method OR 95%CI P-value Pint or Phet # 
Breast  
Overall Inverse-variance weighted 1.02 (0.97, 1.08) 0.47 0.45 
Overall Maximum likelihood 1.02 (0.97, 1.08) 0.47 NA 
Overall MR-Egger 1.02 (0.91, 1.13) 0.78 0.92 
 MR-Egger intercept   0.001(0.010-0.012) 
Overall Weighted Median 1.02 (0.96, 1.08) 0.51 NA 
      ER-positive Inverse-variance weighted 1.00 (0.94, 1.07) 0.99 0.61 
ER-positive Maximum likelihood 1.00 (0.94, 1.07) 0.99 NA 
ER-positive MR-Egger 1.01 (0.90, 1.14) 0.85 0.82 
 MR-Egger intercept   0.001(0.013-0.011) 
ER-positive Weighted Median 1.00 (0.93, 1.07) 0.99 NA 
      ER-negative Inverse-variance weighted 1.02 (0.90, 1.16) 0.75 0.14 
ER-negative Maximum likelihood 1.02 (0.90, 1.16) 0.75 NA 
ER-negative MR-Egger 1.06 (0.83, 1.37) 0.63 0.70 
 MR-Egger intercept   0.005(0.031-0.021) 
ER-negative Weighted Median 1.05 (0.94, 1.18) 0.36 NA 
      Prostate  
Overall Inverse-variance weighted 1.00 (0.93, 1.07) 0.99 0.80 
Overall Maximum likelihood 1.00 (0.93, 1.07) 0.99 ΝΑ 
Overall MR-Egger 1.01 (0.88, 1.16) 0.89 0.88 
 MR-Egger intercept   0.001(0.015-0.013) 
Overall Weighted Median 1.01 (0.94, 1.10) 0.73 ΝΑ 
      Advanced Inverse-variance weighted 1.02 (0.90, 1.16) 0.72 0.58 
Advanced Maximum likelihood 1.02 (0.90, 1.16) 0.72 NA 
Advanced MR-Egger 1.06 (0.78, 1.43) 0.62 0.72 
 MR-Egger intercept   0.004(0.035-0.026) 
Advanced Weighted Median 1.05 (0.91, 1.21) 0.49 NA 
NA: not applicable. The odds ratios represent increase/decrease of risk per 25nmol/L increase in 
25(OH)D. # Phet: P-values of Chi-square Q test for heterogeneity were shown; Pint P-values of MR-Egger 
regression test on the intercept. 
 
 
 
 
 
 
Table 4. Mendelian Randomization estimates between genetically 
predicted 25(OH)D and cancer risk, a sensitivity analysis leaving 
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one SNP out at a time. 
SNP (left out) OR 95%CI P-value 
Overall Breast Cancer 
rs3755967 1.03 (0.93, 1.15) 0.55 
rs10741657 1.01 (0.95, 1.07) 0.71 
rs12785878 1.03 (0.96, 1.09) 0.42 
rs10745742 1.02 (0.96, 1.08) 0.56 
rs8018720 1.03 (0.97, 1.09) 0.33 
rs17216707 1.02 (0.96, 1.08) 0.57 
ER-positive Breast Cancer 
rs3755967 1.02 (0.90, 1.14) 0.80 
rs10741657 1.00 (0.93, 1.07) 0.96 
rs12785878 0.99 (0.93, 1.06) 0.84 
rs10745742 1.00 (0.94, 1.07) 0.96 
rs8018720 1.01 (0.94, 1.08) 0.80 
rs17216707 1.00 (0.93, 1.06) 0.91 
ER-negative Breast Cancer 
rs3755967 0.95 (0.74, 1.22) 0.71 
rs10741657 1.00 (0.87, 1.16) 0.95 
rs12785878 1.06 (0.95, 1.18) 0.27 
rs10745742 1.01 (0.88, 1.17) 0.85 
rs8018720 1.03 (0.91, 1.17) 0.61 
rs17216707 1.02 (0.88, 1.18) 0.82 
Overall Prostate Cancer 
rs3755967 0.97 (0.85, 1.10) 0.64 
rs10741657 1.00 (0.92, 1.07) 0.91 
rs12785878 1.02 (0.94, 1.10) 0.66 
rs10745742 1.00 (0.93, 1.08) 0.99 
rs8018720 1.00 (0.93, 1.07) 0.93 
rs17216707 1.00 (0.93, 1.08) 0.93 
Advanced Prostate Cancer 
rs3755967 0.95 (0.76, 1.19) 0.67 
rs10741657 1.01 (0.88, 1.15) 0.92 
rs12785878 1.07 (0.93, 1.22) 0.35 
rs10745742 1.02 (0.90, 1.16) 0.71 
rs8018720 1.02 (0.90, 1.16) 0.76 
rs17216707 1.03 (0.90, 1.17) 0.69 
The odds ratios represent increase/decrease of risk per 25nmol/L 
increase in 25(OH)D. Odds ratios calculated using inverse variance 
weighted method. 
 
